anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
T cell-focused cancer immunotherapy including checkpoint inhibitors and cell therapies has been rapidly evolving over the past decade. Nevertheless, there remains a major unmet medical need in oncology generally and immuno-oncology specifically. We have constructed an oncolytic adenovirus, Ad5/3-E2F-d24-aMUC1aCD3-IL-2 (TILT-322), which is armed with a human aMUC1aCD3 T cell engager and IL-2. TILT-322 treatment stimulated T cell cytotoxicity through the increased presence of granzyme B, perforin, and interferon-gamma. Additional immune profiling indicated TILT-322 increased gamma delta T cell activation and impacted other cell types such as natural killer cells and natural killer-like T cells that are traditionally involved in cancer immunotherapy. TILT-322 treatment also decreased the proportion of exhausted CD8+ T cells as demarked by immune checkpoint expression in ovarian ascites samples. Overall, our data showed that TILT-322 treatment led to an enhanced T cell activation and reversed T cell exhaustion translating into high antitumor efficacy when given locally or intravenously. The analysis of blood and tumors isolated from an in vivo patient-derived ovarian cancer xenograft model suggested TILT-322 mediated tumor control through improved T cell functions. Therefore, TILT-322 is a promising novel anti-tumor agent for clinical translation.
The Dexcom G6 or current version intended use is for the management of diabetes. It is a small flexible device that records interstitial glucose levels every 5 min and is intended to replace fingerstick blood glucose testing for diabetes treatment decisions. Interpretation of the Dexcom G6 or current version System results should be based on the glucose trends and several sequential readings over time. The system consists of a sensor, transmitter, receiver and mobile app.
PURPOSE: A composition containing a plant extract for oral administration is provided to enable long-term storage of a formulation and to improve convenience. CONSTITUTION: A composition for oral administration contains a Trachelospermi caulis extract or a Trachelospermi caulis extract, silicon dioxide, and a pharmaceutically acceptable excipient. The extract is a dry extract or a soft extract. The excipient is microcrystalline or potassium silicate. The composition is a powder, granules, a hard capsule, or a tablet. A method for manufacturing the composition comprises: a step of preparing one or more extracts among the Trachelospermi caulis extract or a Trachelospermi caulis extract; a step of mixing the extract with silica dioxide and adding ethanol to prepare a mixture; and a step of drying the mixture and completely volatilizing ethanol.
BACKGROUND: Concomitant high-dose cisplatin with radiotherapy is commonly used for treating head and neck squamous cell carcinoma (HNSCC). Cisplatin, often used with radiotherapy, is known for causing irreversible sensorineural hearing loss, with individual variability suggesting a genetic component. This study aims to enhance the predictive ability of the clinical prediction model for cisplatin-induced hearing loss (CIHL) in HNSCC patients, as outlined in Theunissen et al., by incorporating significant genetic variants.
METHODS: Conducted at the Netherlands Cancer Institute, this retrospective study included 74 patients treated between 1997 and 2011. Thirty-one SNPs that were previously associated with CIHL or other cisplatin-induced toxicities were identified and incorporated into the model. The primary outcome measured was the change in decibels at posttreatment 1-2-4 kHz hearing levels per additional minor allele of these SNPs, evaluated using linear mixed-effects regression models. The model's predictive accuracy was determined by the area under the curve (AUC) using 10-fold cross-validation.
RESULTS: The rs2289669 SNP in the SLC47A1/MATE1 gene was linked to a significant 2.67 dB increase in hearing loss per allele (95% CI 0.49-4.86, p = 0.017). Incorporating rs2289669 improved the model's AUC from 0.78 to 0.83, a borderline significant improvement (p = 0.073).
CONCLUSIONS: This study underscores the importance of the rs2289669 SNP in CIHL and demonstrates the potential of combining genetic and clinical data for enhanced predictive models in personalized treatment strategies.
Head and neck cancer (HNC) is the fifth most common cancer in the world, especially in South China. The incidence of depression and anxiety in HNC patients after radiotherapy is as high as 12% - 45% due to appearance changes, decreased swallowing function, dry mouth, pain and other discomfort. At the same time, radiotherapy, as mainstay of therapy for HNC, also causes different degrees of damage to the brain around the tumor, leading to secondary cognitive dysfunction. Depression, anxiety and cognitive impairment seriously affect the quality of life of HNC patients after radiotherapy. Recent studies have found that votioxetine has multimodal pharmacodynamic activity, which can not only improve symptoms of depression, but also significantly improve the cognitive function of patients. In this study, investigators will discuss the therapeutic effect of vortioxetine on the depression after radiotherapy in HNC patients through a multi-center, randomized and double-blind comparative clinical trial.
PURPOSE:To obtain a milky bath medicine containing a water insoluble inorganic substance coated with a water soluble high polymer substance containing an aqueous pigment as an essential ingredient and capable of providing emulsion like bath rich in color tone. CONSTITUTION:50-200 pts.wt. water soluble high polymer substance (e.g., dextrin) and 0.001-20 pts.wt. water soluble pigment are added to 50-300 pts.wt. purified water and stirred and dissolved in the water. Then 50-150 pts.wt. water insoluble inorganic substance (e.g., titanium oxide) is added thereto and the mixture is stirred for 10-15 min at ordinary temperature to disperse the inorganic substance into the solution. The dispersed liquid is dried at 100-150 deg.C for 10-30hr and pulverized into 60-200 mesh size by a grinder to afford a water insoluble inorganic substance powder coated with a water soluble high polymer substance containing a water soluble pigment, which is then blended with a bath medicine such as inorganic salts, organic salts, crude medicines, oil and fats or alcohols so as to contain at an amount of 0.1-20wt.% based on total bath medicine and uniformly stirred under ordinary temperature to provide the aimed product.
The invention discloses a formula of a compound sodium sulfide and artemisia oil injection emulsion for treating hemorrhoids, as well as a preparation method and application thereof. The emulsion is a brand-new compound medicine which has multiple effects of necrotizing hemorrhoids, stopping bleeding, sterilizing and the like, has a remarkable treatment effect and can be used for shortening the clinical curing time and relieving swelling and pain around the anal verge, so that wound edge secretion can be reduced, the local part of a patient feels cool and comfortable, and the patient can easily accept the medicine. The compound sodium sulfide and artemisia oil injection emulsion is prepared from the following raw materials and auxiliary materials: sodium sulfide, artemisia oil, menthol, borneol, solubilizing emulsifier, glycerinum and water for injection. Furthermore, the invention further provides a preparation method of the compound sodium sulfide and artemisia oil injection emulsion. In the preparation process, menthol and borneol can be dissolved without diethyl ether, ethanol and other organic solvents, so that the preparation process is simple and safe, and the production cost is low. The preparation method is more suitable for industrial production, and is convenient for market popularization and application.
Observational arm. Children (6-17 years) with any type of OI who are not receiving bisphosphonate treatment. Changes in hearing, quality of life, and bone density will be observed for the duration of the study.
PURPOSE:To provide a novel cosmetic having high dispersion stability and UV-absorbing property, by using a water-insoluble salt of humic acid or nitrohumic acid as a cosmetic component. CONSTITUTION:The objective cosmetic contains one or more kinds of water- insoluble humic acid salt or nitrobumic acid salt prepared by reacting humic acid or nitrohumic acid with a cation such as Ca, Mg, Zn, Al, Fe, alkylammonium, etc. in an amount of 0.001-60wt%, preferably 0.01-40wt% based on the whole cosmetic composition. The salt of humic acid or nitrohumic acid is black or brown powder insoluble in water and oil, resistant to coagulation, having excellent dispersibility in water or oil, and resistant to oxidation. Accordingly, the salt can be pulverized to fine powder, and the obtained powder has strong coloring power, high thermal stability and resistance to acid, and gives hardly separable intimate mixture with other powder. It prevents the sunburn, aging of skin, and canceration of the skin.
BACKGROUND: Outcomes of Marfan syndrome (MFS) patients after total knee arthroplasty (TKA) are poorly documented in the literature. The purpose of this study was to evaluate MFS as a potential risk factor for complications after TKA.
METHODS: Using a national private payer insurance database from 2010 to 2022, MFS patients undergoing primary TKA were identified and compared to 10:1 matched controls based on age, sex, obesity, diabetes mellitus, and a comorbidity index. A total of 4,092 patients undergoing primary TKA were analyzed, of which 372 had MFS. Multivariable logistic regression analyses were done for medical complications up to 90 days and surgical complications up to 2 years. 90-day emergency department-visits and inpatient readmissions were also documented.
RESULTS: Compared to the matched controls, patients who have MFS displayed elevated rates of surgical complications, including prosthetic instability (1-year, odds ratio (OR) 3.88, 95% confidence interval (CI) [1.58 to 8.66]; 2-year, OR 4.39, 95% CI [2.16 to 8.44]), and revision surgery (2 year, OR 1.79, 95% CI [1.05 to 2.91]). Additionally, patients who have MFS demonstrated significant higher rates of medical complications, including aortic dissection (2.15 versus 0%) and transfusion (OR 2.63, 95% CI [1.31 to 4.90]).
CONCLUSIONS: Patients who have MFS are at higher risks of postoperative complications after TKA, encompassing both medical and surgical complications. Specifically, patients who have MFS have a significantly higher likelihood of experiencing prosthetic instability and requiring revision surgery. Given these results, it is crucial for orthopedic surgeons and patients alike to consider these risks when determining a course of TKA for patients who have MFS.
Drug-resistant coliphage and application thereof. Classified and named as Escherichia phase vB _ EcoP-EG1 with the accession number: CCTCC M2018562, and the preservation date is 8 months and 21 days in 2018. The bacteriophage Escherichia phase vB _ EcoP-EG1 has stable property, short life cycle and strong host bacterium cracking capability. The results of genome and protein mass spectrometry show that the phage Escherichia phase vB _ EcoP-EG1 does not encode toxic proteins. Meanwhile, the bacteriophage Escherichia phase vB _ EcoP-EG1 can infect and crack a plurality of strains of clinically randomly separated multi-drug-resistant Escherichia coli, and particularly has a good killing effect on urethral pathogenic Escherichia coli. In conclusion, Escherichia phase vB _ EcoP-EG1 is a good candidate phage for phage therapy, and can be used as a single preparation or mixed with other phage to form a cocktail preparation for resisting infection caused by clinical multi-drug resistant Escherichia coli.
The Danish national colorectal cancer screening program includes all citizens aged 50-74 years, who are invited biennially to a fecal test for invisible blood in the stool. If the test is positive the citizen is invited for a colonoscopy. 90% of the test-positive undergo colonoscopy. The detected cancers are at a significant earlier stage and survival from screening detected cancer is higher. It is also expected that cancer incidence will drop due to removal of the advanced adenomas before they develop into cancer. Although initial results are positive, there is room for improvement. Additionally there are rare but serious complications to colonoscopy in the form of bleeding or bowel perforation.

Through four years the investigators have tested the colon capsule endoscopy method, and find that the investigation is associated with significantly less discomfort and that the diagnostic ability to find polyps \> 1 cm is better than colonoscopy.
Intermittent theta burst stimulation, a derivative of repetitive transcranial magnetic stimulation, has been applied to improve cognitive deficits. However, its efficacy and mechanisms in enhancing cognitive function in patients with amnestic mild cognitive impairment compared with traditional repetitive transcranial magnetic stimulation paradigms remain unclear. This study recruited 48 amnestic mild cognitive impairment patients, assigning them to intermittent theta burst stimulation, repetitive transcranial magnetic stimulation, and sham groups (5 times/wk for 4 wk). Neuropsychological assessments and functional magnetic resonance imaging data were collected pre- and post-treatment. Regarding efficacy, both angular gyrus intermittent theta burst stimulation and repetitive transcranial magnetic stimulation significantly improved general cognitive function and memory compared to the sham group, with no significant difference between the 2 treatment groups. Mechanistically, significant changes in brain activity within the temporoparietal network were observed in both the intermittent theta burst stimulation and repetitive transcranial magnetic stimulation groups, and these changes correlated with improvements in general cognitive and memory functions. Additionally, intermittent theta burst stimulation showed stronger modulation of functional connectivity between the hippocampus, parahippocampal gyrus, and temporal regions compared to repetitive transcranial magnetic stimulation. The intermittent theta burst stimulation and repetitive transcranial magnetic stimulation can improve cognitive function in amnestic mild cognitive impairment patients, but intermittent theta burst stimulation may offer higher efficiency. Intermittent theta burst stimulation and repetitive transcranial magnetic stimulation likely enhance cognitive function, especially memory function, by modulating the temporoparietal network.
Group IPT consists of 12 weeks of virtually delivered therapy by two co-therapists via Zoom to a group of 6-8 women. The 12 weeks consist of 15 sessions over 12 weeks of group IPT taking place virtually via Zoom (2 sessions per week for the first 4 weeks (acute phase) then once a week for 6 weeks, then a two-week space before the last session).
In an open-label trial, 48 previously untreated patients with peripheral CMV retinitis were randomized to either immediate treatment with VISTIDE (5 mg/kg once a week for 2 weeks, then 5 mg/kg every other week), or to have VISTIDE delayed until progression of CMV retinitis14. Patient baseline characteristics and disposition are shown in Table 3. Of 25 and 23 patients in the immediate and delayed groups respectively, 23 and 21 were evaluable for retinitis progression as determined by retinal photography. Based on masked readings of retinal photographs, the median [95% confidence interval (CI)] times to retinitis progression were 120 days (40, 134) and 22 days (10, 27) for the immediate and delayed therapy groups, respectively. This difference was statistically significant. However, because of the limited number of patients remaining on treatment over time (3 of 25 patients received VISTIDE for 120 days or longer), the median time to progression for the immediate therapy group was difficult to precisely estimate. Median (95% CI) times to the alternative endpoint of retinitis progression or study drug discontinuation (including adverse events, withdrawn consent, and systemic CMV disease) were 52 days (37, 85) and 22 days (13, 27) for the immediate and delayed therapy groups, respectively. This difference was statistically significant. Time to progression estimates from this study may not be directly comparable to estimates reported for other therapies.
BACKGROUND: Patients with cirrhosis have a normal to increased thrombin generation (TG) capacity in platelet-poor plasma (PPP). By reflecting the contribution of all circulating blood cells, whole blood (WB) TG may allow a more physiological assessment of coagulation.
OBJECTIVES: We compared WB-TG vs PPP-TG in patients with cirrhosis.
METHODS: Assessment of coagulation included routine tests, factor VIII, natural anticoagulants, PPP-TG, and WB-TG. TG assays were performed with and without thrombomodulin. Twenty-five healthy subjects were included as controls.
RESULTS: We included 108 patients (Child-Pugh A/B/C, 44/24/40). Compared with controls, patients had significantly lower platelet count, longer international normalized ratio, higher FVIII, and lower levels of protein C/S and antithrombin. Regarding thrombomodulin-modified TG assays, in compensated cirrhosis, both PPP-TG and WB-TG indicated an increased TG capacity, as reflected by an endogenous thrombin potential (ETP) significantly higher than controls. In contrast, in decompensated cirrhosis, PPP-TG indicated a hypercoagulable state with increased ETP, higher peak height, and shorter time-to-peak than controls, whereas WB-TG revealed a progressive impairment of TG kinetics and total capacity, ultimately resulting in a profound hypocoagulable state in patients with Child-Pugh C cirrhosis (ie, significant prolongation of lag time and time-to-peak with reduction of both ETP and peak height). In decompensated patients, bacterial infections and severity of anemia were associated with a further reduction of both ETP and peak height.
CONCLUSION: Compensated cirrhosis is associated with an increased TG capacity. In decompensated cirrhosis, contrary to PPP-TG, which indicates hypercoagulability, WB-TG shows a significant hypocoagulable state. The clinical value of these findings deserves further investigation.
An apparatus includes a first production line configured to generate aqueous ozone with a first ozone concentration. The apparatus also includes an additional production line configured to generate aqueous ozone with an additional ozone concentration. The first production line and the additional production line include a flow switch, where fluid is configured to flow through the flow switch. The first production line and the additional production line include an ozone generator, where the ozone generator is configured to generate ozone when the fluid flows through the flow switch. The first production line and the additional production line include a fitting coupled to the flow switch and the ozone generator, where the fitting is configured to combine the generated ozone and the fluid to generate the aqueous ozone. The first production line is configured to generate aqueous ozone independently from the additional production line.
Introduction: Peri-implant mucositis (PM) is an inflammatory disease induced by the accumulation of bacteria (biofilm) around dental implants, which can be modulated by individual characteristics of the patient, as well as by numerous factors related to a greater accumulation of biofilm in peri-implant tissues. Without correct regular maintenance, this entity can progress to peri-implantitis, a disease in which there is loss of bone supporting the implant. However, the strength of the association of the factors with the appearance of PM remains weak and incidence studies are limited due to their design and methodological inconsistencies. Therefore, the objective of this study is to determine the incidence of PM in patients with treated periodontitis and enrolled in periodontal maintenance and to evaluate the associated risk indicators.

Material and method: An analytical prospective observational study will be carried out, with an initial follow-up of 12 months. Patients with treated periodontitis and enrolled in periodontal maintenance will be selected, consecutively. They need to have implants placed in the Periodontics Specialist Clinic and are going to be rehabilitated at the UCM School of Dentistry. Peri-implant and periodontal clinical records, radiographic records, demographic variables, patient-based variables, and submucosal microbiological samples will be taken on the day of crown placement and after 6 and 12 months. The calculation of the sample size estimates the need to recruit 227 patients. The results will be analyzed using regression models.
A device can automatically count, speciate, and determine infectivity of eggs of parasites in food animals. The device can include a chamber that can receive a sample specimen. Additionally, the device can include a light source. The light source can illuminate a field of view of the sample specimen in the chamber. The device can further include a microscope objective to magnify the field of view of the sample specimen. The device can include a camera. The camera can image the field of view of the sample specimen. The camera can further produce an on-site dataset of images. Additionally, the camera can provide the on-site dataset of images to a trained machine-learning model for analysis of at least one species of parasites.
PURPOSE: To obtain a medicine, for acute hepatic insufficiency, esp. for fulminant hepatitis, containing, as active ingredient, a tissue factor pathway inhibitor. CONSTITUTION: This medicine contains, active ingredient, a human tissue factor pathway inhibitor (TFPI). Combination of this medicine with another appropriate established vehicle (e.g. human serum albumin) is made and pharmaceutical preparations are manufactured by convertional means in the form of oral administration agent, parenteral administration agent (pref. intravenous administration agent). This inhibitor is produced from the blood of humans or other mammals, or by the gene recombinant technology. This inhibitor belongs to the same Kunitz-type protease inhibitor group as for aprotinin, binding, via activated factor X, to a conjugate composed of tissue factor and activated factor VII and inhibiting the activity.
Data collection session will involve the participant completing the Tinnitus Functional Index (TFI) and Demographics and Tinnitus History Questionnaire (D\&THQ), which will provide the investigators with information about their personal tinnitus history including subjective characteristics such as loudness. The D\&THQ consists of questions selected from the European School for Interdisciplinary Tinnitus Research Screening Questionnaire (ESIT-SQ). Participants will undergo a standard hearing test, which will inform the investigators of any hearing loss. The participant's head shape will be digitized to aid in the spatial localization of the MEG signal. The participant will then undergo 40 minutes of MEG scanning (10 minutes of resting state without tDCS, 20 minutes of resting state MEG with either active or sham tDCS, and then another 10 minutes of resting state MEG without tDCS. The first 10 minutes will serve as a baseline of resting state oscillatory brain activity. The concurrent tDCS and MEG recording will allow the investigators to observe changes in oscillatory brain activity during tDCS. The last 10 minutes of MEG recording will allow the investigators to see whether any changes in oscillatory activity persist after the stimulation ends. After the MEG recording has finished, the participant will undergo an anatomical MRI scan. This will allow the investigators to take the participants' individual brain morphology into account when analysing the source of the MEG signal.